Pep Gen Inc. PEPG
We take great care to ensure that the data presented and summarized in this overview for PepGen Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PEPG
View all-
Ra Capital Management, L.P. Boston, MA10.7MShares$12.4 Million0.26% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct2.76MShares$3.2 Million0.01% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.51MShares$1.75 Million0.0% of portfolio
-
Viking Global Investors LP1.48MShares$1.72 Million0.01% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA1.35MShares$1.57 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.04MShares$1.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA937KShares$1.09 Million0.0% of portfolio
-
Laurion Capital Management LP New York, NY811KShares$940,4820.02% of portfolio
-
Woodline Partners LP San Francisco, CA692KShares$802,1740.0% of portfolio
-
Suvretta Capital Management, LLC New York, NY300KShares$348,0000.01% of portfolio
Latest Institutional Activity in PEPG
Top Purchases
Top Sells
About PEPG
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at PEPG
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 30
2025
|
Paul Streck EVP, Head of R&D |
BUY
Open market or private purchase
|
Direct |
8,375
+23.15%
|
$8,375
$1.24 P/Share
|
|
May 20
2025
|
Kasra Kasraian Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,750
+50.0%
|
-
|
|
Apr 17
2025
|
James G Mc Arthur President and CEO |
BUY
Open market or private purchase
|
Direct |
10,000
+8.07%
|
$10,000
$1.36 P/Share
|
|
Apr 08
2025
|
James G Mc Arthur President and CEO |
BUY
Open market or private purchase
|
Direct |
41,500
+28.54%
|
$41,500
$1.15 P/Share
|
|
Mar 03
2025
|
Mary Beth De Lena General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
13,400
+47.24%
|
-
|
|
Mar 03
2025
|
Paul Streck EVP, Head of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
19,430
+50.0%
|
-
|
|
Mar 03
2025
|
Noel Donnelly Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,283
+48.27%
|
-
|
|
Mar 03
2025
|
James G Mc Arthur President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
60,719
+49.31%
|
-
|
|
Feb 26
2025
|
Mary Beth De Lena General Counsel |
SELL
Open market or private sale
|
Direct |
1,432
-47.73%
|
$1,432
$1.68 P/Share
|
|
Feb 26
2025
|
Noel Donnelly Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,527
-47.72%
|
$1,527
$1.68 P/Share
|
|
Feb 24
2025
|
Mary Beth De Lena General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+50.0%
|
-
|
|
Feb 24
2025
|
Noel Donnelly Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,200
+50.0%
|
-
|
|
Jul 25
2024
|
Michelle L Mellion Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,571
-100.0%
|
$136,278
$18.06 P/Share
|
|
Jul 25
2024
|
Michelle L Mellion Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,571
+50.0%
|
$75,710
$10.21 P/Share
|
|
Jul 24
2024
|
Michelle L Mellion Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
201
-100.0%
|
$3,618
$18.01 P/Share
|
|
Jul 24
2024
|
Michelle L Mellion Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
201
+50.0%
|
$2,010
$10.21 P/Share
|
|
Jul 18
2024
|
Michelle L Mellion Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
12,625
-100.0%
|
$227,250
$18.2 P/Share
|
|
Jul 18
2024
|
Michelle L Mellion Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,625
+50.0%
|
$126,250
$10.21 P/Share
|
|
Jul 16
2024
|
Michelle L Mellion Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,901
-100.0%
|
$106,218
$18.0 P/Share
|
|
Jul 16
2024
|
Michelle L Mellion Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,901
+50.0%
|
$59,010
$10.21 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 140K shares |
|---|---|
| Open market or private purchase | 59.9K shares |
| Open market or private sale | 2.96K shares |
|---|